Tamoxifen increases apoptosis but does not influence markers of proliferation in an MCF-7 xenograft model of breast cancer

Breast

Volumn 9, Issue 2, 2000, Pages 96-106

  Hawkin, R A ^a   Arends, M J ^a   Ritchie, A A ^b   Langdon, S ^b   Miller, W R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; IMMUNOCYTOCHEMISTRY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT;

EID: 0034102667     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0140     Document Type: Article

References (57)

1. Jordan V C. The strategic use of antioestrogens to control the development and growth of breast cancer. Cancer (Supplement). 70:1992;977-982.
2. Kessel D. Interactions among membrane transport systems: anthracyclins, calcium antagonists and antioestrogens. Biochem Pharmacol. 35:1986;2825-2826.
3. Hu XF, Nadalin G, De Luise M. Circumvention of Doxorubicin resistance in multi-drug-resistant leukaemia and lung cancer cells by the pure antioestrogen ICI 164384. Europ J Cancer. 27:1991;773-777.
4. Sudo K, Monsuma F J, Katzenellenbogen B S. Antiestrogen-binding sites distinct from the estrogen receptor : subcellular localisation, ligand specificity and distribution in tissues of the rat. Endocrinology. 112:1983;425-434.
5. Watts C K, Sutherland R L. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites. Molec Pharmacol. 31:1987;541-551.
6. Sutherland R L, Reddel R R, Murphy L C, Taylor I W. Effects of antiestrogens on cell cycle progression. Jordan V C. Estrogen/antiestrogen action and breast cancer therapy. 1986;266-281 University of Wisconsin Press, Madison/London.
7. Butler B B, Kelsey W H. Effects of tamoxifen and 4-hydroxy-tamoxifen on synchronised cultures of human breast cancer cell line MCF-7. Breast Cancer Res Treat. 11:1988;37-43.
8. Wang T T Y, Phang J M. Effects of estrogen on the apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55:1995;2487-2489.
9. Perry R R, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Annals of Surg Oncol. 2:1995;238-245.
10. Kang Y, Cortina R, Perry R R. Role of c-myc in Tamoxifen- induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst. 88:1996;279-284.
11. Chen H, Tritton T R, Kenny N. Tamoxifen induces TGF-β1 activity and apoptosis of human breast cancer cells in vitro. J Cellular Biochem. 61:1996;9-17.
12. Lim J S, Frenkel K, Troll W. Tamoxifen suppresses TP- induced hydrogen peroxide formation by neutrophils. Cancer Res. 52:1992;4969-4972.
13. Bhimani R S, Troll W, Grunberger D, Frenkel K. Inhibition of oxidative stress in Hela cells by chemopreventative agents. Cancer Res. 53:1993;4528-4533.
14. Haran E F, Maretzek A F, Goldberg I. Tamoxifen enhances cell death in implanted MCF-7 breast cancer by inhibiting endothelium growth. Cancer Res. 54:1994;5511-5514.
15. Gagliardi A, Collins D C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 53:1993;533-535.
16. Noguchi S, Motomura K, Inaji H. Down-regulation of Transforming growth factor-α by Tamoxifen in human breast cancer. Cancer. 72:1993;131-136.
17. Perry R R, Kang Y, Greaves B R. Relationship between Tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Brit J Cancer. 72:1995;1441-1446.
18. Nickerson T, Huynh H, Pollak M. Insulin-like Growth Factor Binding Protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochem Biophys Res Communications. 237:1997;690-693.
19. Maas R A, Bruning P F, Top B. Growth arrest-associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR; potential early indicators of treatment response. Cancer Lett. 97:1995;107-116.
20. Wong M S, Murphy L C. Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol Biol. 39:1991;39-44.
21. Watts C K., Sweeney K J, Warlters A. Antiestrogen regulation of cell cycle progresion and cyclin D1 gene expresion in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 31:1994;95-105.
22. Westley B, May F E B, Brown A M C. Effects of antiestrogens on the estrogen-regulated ps2 RNA and the 52 and 160 kDa proteins in MCF-7 cells and two Tamoxifen-resistant cell lines. J Biol Chem. 259:1984;10030-10035.
23. Horwitz K B, McGuire W L. Estrogen control of progesterone receptors in human breast cancer. J Biol Chem. 253:1978;2223-2228.
24. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 20:1980;352-362.
25. Horgan K, Cooke E, Hallett M B, Mansel R E. Inhibition of protein kinase C-mediated signal transduction by Tamoxifen. Importance for antitumour activity. Biochem Pharmacol. 35:1986;4463-4465.
26. Keen J C, Miller E P, Bellamy C. P-glycoprotein and resistance to tamoxifen. Lancet. 343:1994;147-1048.
27. Hawkins R A. Receptors in the management of breast cancer. Brit J Hospital Med. 34:1985;160-164.
28. Anderson E D C, Forrest A P M, Levack P A. Response to endocrine manipulation and oestrogen receptor concentration in large operable breast cancer. Brit J Cancer. 60:1989;223-226.
29. Gaskell D J, Hawkins R A, Sangster K. Relation between immunocytochemical estimation of oestrogen receptors in elderly patients with primary breast cancer and response to tamoxifen. Lancet. i:1989;1044-1046.
30. Kean, J, C. The response to the primary systemic treatment of breast cancer.
31. Gaskell D J, Hawkins R A, de Carteret S. Indications for primary tamoxifen therapy in elderly women with breast cancer. Brit J Surg. 79:1992;1317-1320.
32. Cameron D A, Anderson E D C, Levack P A. Primary systemic therapy for operable breast cancer- 10-year survival after chemotherapy and hormone therapy. Brit J Cancer. 76:1997;1099-1105.
33. Keen J C, Dixon J M, Miller E P. The expression of Ki-s1 and bcl-2 and the response to primary Tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat. 44:1997;123-133.
34. Makris A, Powles T J, Allred S. Changes in hormone receptors and proliferation markers in Tamoxifen-treated breast cancer patients and the relationship with response. Breast Cancer Res Treat. 48:1998;11-20.
35. Kenny F S, Willsher P C, Gee J M W. Change in expression of ER and bcl-2 predict for quality and duration of response in endocrine-sensitive breast cancer. The Breast. 6:1997;0-10.
36. 67antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed, fromalin-fixed paraffin sections. J Pathol. 168:1992;357-363.
37. Ostrowski M I, Chakraborty S, Laurcirica R. Quantitative image analysis of MIB-1 immunoreactivity. A comparison with flow cytometric assessment of proliferative activity in invasive carcinoma of the breast. Analyt and Quantitative Cytol and Histol. 17:1995;15-24.
38. Gee J M W, Robertson J R W, Ellis A O. Immunocytochemical localisation of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 59:1994;619-628.
39. Leek R D, Kaklamanis L, Pezzella F. Bcl-2 in normal breast and carcinoma, association with oestrogen receptor-positive, EGFR-negative tumours and in-situ cancer. Brit J Cancer. 69:1994;135-139.
40. Adams J M, Corey S. The Bcl-2 family: arbiters of cell survival. Science. 1998;1322-1325.
41. Cameron D A, Ritchie A, Langdon S. Tamoxifen-induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat. 45:1997;99-107.
42. Arends M J, McGregor A H, Toft N J. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Brit J Cancer. 68:1993;1127-1133.
43. Arends M J, McGregor A H, Wyllie A H. Apoptosis is inversely related to necrosis and determines net growth rate in tumours bearing constitutively expressed myc, ras and HPV oncogenes. Amer J Pathol. 114:1994;1045-1057.
44. Mullen P, Ritchie A, Langdon S P, Miller W R. Effects of matrigel on the tumorigenicity of human breast and ovarian cell lines. Int J Cancer. 67:1996;816-820.
45. Hawkins R A, Tesdale A L, Killen M E. Prospective evaluation of prognostic factors in operable breast cancer. Brit J Cancer. 74:1996;1469-1478.
46. Arends M J, Wyllie A H. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol. 136:1991;593-608.
47. Arends M J, Harrison D J. Apoptosis: molecular aspects and pathological perspective. Crocker J. Molecular Biology in Histopathology. 1994;151-170 John Wiley, Chichester.
48. MacCallum J, Cummings J, Dixon J M, Miller W R. Solid phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues. J Chromatography B. 698:1997;269-275.
49. Sarkaria J N, Gibson D F C, Jordan V C. Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labelling flow cytometry. Cancer Res. 53:1993;4413-4417.
50. Brunner N, Bronzert D, Vindelov L L. Effect of growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 49:1989;1515-1520.
51. Kyprianou N, English H F, Davidson N E, Isaacs J T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51:1991;162-166.
52. Dowsett M, Archer C, Assershon L. Clinical studies of apoptosis and proliferation in breast cancer. Endocrine-Related Cancer. 6:1999.
53. Wyllie A H. The biology of cell death in tumours. Anticancer Research. 5:1985;131-136.
54. Page D L, Simpson J F. Measures of proliferation in breast cancer: practicality and utility. The Breast. 6:1997;169-170.
55. Daltrey I R, Lewis C E, Green M. Preoperative Tamoxifen: the effect on cytological prognostic markers. Breast. 6:1997;0-13.
56. Cameron D A, Keen J, Anderson T J. Tamoxifen alters the relationship between bcl-2 and apoptosis in breast cancer. Breast. 6:1997;0-9.
57. Connor A J M, Pinder S E, Elston C W. Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB-1 antibody. Breast. 6:1997;171-176.